Patent classifications
C12N15/70
BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
BIOCATALYTIC TECHNIQUES
The present invention relates to a cytochrome P450 enzyme comprising the amino acid sequence set forth in SEQ ID NO: 3, or a variant thereof having an amino acid sequence having at least 95% identity thereto and having CYP450 activity. The cytochrome P450 enzyme provided herein was isolated from Streptomyces eurythermus NRRL 2539 and has a wide substrate range and high activity, and may be used to oxidate organic compounds.
BIOCATALYTIC TECHNIQUES
The present invention relates to a cytochrome P450 enzyme comprising the amino acid sequence set forth in SEQ ID NO: 3, or a variant thereof having an amino acid sequence having at least 95% identity thereto and having CYP450 activity. The cytochrome P450 enzyme provided herein was isolated from Streptomyces eurythermus NRRL 2539 and has a wide substrate range and high activity, and may be used to oxidate organic compounds.
EXPRESSION OF ELECTRICALLY CONDUCTIVE PROTEIN NANOWIRES IN ESCHERICHIA COLI
The present invention provides, in various embodiments, genetically modified aerobic bacteria, polynucleotides and methods for expressing and/or harvesting electrically conductive protein nanowires (e-PNs). The present invention also provides e-PNs produced using the genetically modified aerobic bacteria, polynucleotides and methods.
METHOD FOR PREPARING RECOMBINANT HUMAN NERVE GROWTH FACTOR
Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.
METHOD FOR PREPARING RECOMBINANT HUMAN NERVE GROWTH FACTOR
Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.
COMPOSITIONS AND METHODS OF USING INDUCIBLE SIGNALING FOR TUNABLE DYANMICS IN MICROBIAL COMMUNITIES
Provided herein are compositions and methods for modulating induction of quorum sensing in bacterial cells. For example, provided herein is a method of inducing method of inducing quorum sensing, where the method includes: culturing a bacterial strain, wherein the bacterial strain comprises a first nucleic acid sequence encoding a first activator polypeptide, wherein expression of the first activator polypeptide produces a quorum sensing molecule precursor; a second nucleic acid sequence encoding a second activator polypeptide, wherein expression of the second activator polypeptide produces a quorum sensing; a third nucleic acid sequence encoding a third activator polypeptide that is capable of activating the quorum sensing system; a fourth nucleic acid sequence encoding a gene of interest, and contacting the bacterial strain with an inducer molecule; and converting the inducer molecule into a quorum sensing molecule, thereby allowing induction of quorum sensing.
COMPOSITIONS AND METHODS OF USING INDUCIBLE SIGNALING FOR TUNABLE DYANMICS IN MICROBIAL COMMUNITIES
Provided herein are compositions and methods for modulating induction of quorum sensing in bacterial cells. For example, provided herein is a method of inducing method of inducing quorum sensing, where the method includes: culturing a bacterial strain, wherein the bacterial strain comprises a first nucleic acid sequence encoding a first activator polypeptide, wherein expression of the first activator polypeptide produces a quorum sensing molecule precursor; a second nucleic acid sequence encoding a second activator polypeptide, wherein expression of the second activator polypeptide produces a quorum sensing; a third nucleic acid sequence encoding a third activator polypeptide that is capable of activating the quorum sensing system; a fourth nucleic acid sequence encoding a gene of interest, and contacting the bacterial strain with an inducer molecule; and converting the inducer molecule into a quorum sensing molecule, thereby allowing induction of quorum sensing.
METHOD FOR ENHANCING WATER SOLUBILITY OF TARGET PROTEIN BY WHEP DOMAIN FUSION
The present invention relates to a fusion protein for enhancing expression efficiency of a target protein. More specifically, the present invention relates to a glutamyl-prolyl-tRNA synthetase from human (hEPRS) WHEP domain (including WHEP domains TRS-1, TRS-2, and TRS-3 which locate at middle sites of the EPRS protein, and linkers connecting the three domains therethrough). When used as a fusion protein for expressing a target protein in E. coli, the hEPRS WHEP domain according to the present invention enhanced water solubility of the target protein.